Search Results - sanjay+srivastava

6 Results

Sort By:

Anticancer effects of Pimavanserin, a known anti-Parkinson drug

Cancer treatment methods must meet rigorous constraints before being approved by the FDA for administration to patients. Consequently, it is estimated that in 2012, more than 50% of the diagnosed cancer cases died worldwide due to these constraints preventing usage and treatment. It is becoming increasingly important to present more options for cancer...

Published: 12/17/2018 | Inventor(s): Sanjay Srivastava, Sharavan Ramachandran

Keywords(s):

Category(s): Cancer Therapeutics

Drug Combinations to Overcome Resistance to BRAF and MEK Inhibitors

The drug Vemurafenib is one of the few treatment options for late-stage melanoma currently available. However, upon either single or chronic treatment with Vemurafenib, the cancer cells develop mechanisms of resistance to the drug. Other drugs available in the market such as Mek1/2 inhibitors and BRAF inhibitors fail to overcome Vemurafenib resistance....

Published: 11/28/2018 | Inventor(s): Sanjay Srivastava, Neel Fofaria

Keywords(s):

Category(s): Cancer Therapeutics, Pharmaceutical, Therapeutics

Formulations (oral and topical cream) containing anti-cancer agents to prevent or treat melanoma

Melanoma is the most serious type of skin cancer and develops in the cells that produce melanin. Treatment for early-stage melanomas usually include surgery to remove the melanoma. If the melanoma has spread beyond the skin, treatment options may include surgery to remove affected lymph nodes and chemotherapy. An effective new drug delivery system...

Published: 7/2/2018 | Inventor(s): Sanjay Srivastava, Neel Fofaria, Hussaini Qhattal

Keywords(s): Cancer, consumer products, Drug delivery, Pharmaceuticals, Therapeutics

Category(s): Therapeutics, Cancer Therapeutics, Plant Derivative

Method to Enhance Treatment of Metastatic Melanoma with BRAF Inhibitors

Malignant melanoma is the most lethal form of skin cancer and accounts for almost 80% of skin cancer deaths. About 60% of melanomas have a mutation in the BRAF oncogene at V600E. The FDA recently approved (January 2014) the combination of a BRAF inhibitor (Dabrafenib) and a MEK 1/2 inhibitor (Trametinib) to treat this type of melanoma. A problem...

Published: 7/2/2018 | Inventor(s): Sanjay Srivastava, Neel Fofaria

Keywords(s): Cancer, Medicine, Molecular Medicine, Therapeutics

Category(s): Cancer Therapeutics, Pharmaceutical, Therapeutics

Mechanism of the Ineffectiveness of Panabinostat against Pancreatic Cancer (Solid Malignancies) and Strategies to Increase its Efficacy

Emerging evidence suggests that histone deacetylase inhibitors (HDACi) play a significant role in cancer treatment by allowing for the expression of a tumor suppressant gene. However, the inventors have discovered that HDACi also up-regulates the expression of Bcl2 protein, which leads to resistance to chemotherapy in almost every tumor model. Therefore,...

Published: 7/2/2018 | Inventor(s): Sanjay Srivastava, Srinivas Boreddy

Keywords(s): Anti-inflammatory, Biomarker, Cancer, Gastrointestinal, integrin mediated cell signaling, nutraceuticals, Therapeutics

Category(s): Cancer Therapeutics

Overcoming Vemurafinib Resistance in Metastatic Melanoma by inhibiting Mcl-1

Malignant melanoma is the deadliest form of skin cancer, accounting for seventy-five percent of skin cancer related deaths. Until recently, treatment options for late stage metastatic cancer had been limited. In 2011, the FDA approved vemurafenib, a BRAF inhibitor, for the treatment of late stage metastatic cancer that bears the BRAF oncogene. Patients...

Published: 7/2/2018 | Inventor(s): Sanjay Srivastava, Neel Fofaria

Keywords(s): Cancer, Medicine

Category(s): Cancer Therapeutics